Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
Status:
Completed
Trial end date:
2016-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this single visit extension study is to explore immune status in RRMS patients
treated for at least 48 months with fingolimod. Long-term changes in T cell counts will be
compared to short-term changes in immune status (baseline to month 6) after treatment start
with fingolimod as assessed in the original Biobank study (CFTY720DDE01).